Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

about

Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics.Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications

P2860

Q47315881-07B459B8-C9B6-4489-8E90-1FBBD877B873 Q58760425-EC73EE74-6FA2-4370-BDF1-7ABFDE400DE7

P2860

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

Item

http://www.wikidata.org/entity/Q38831784

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

@en

type

Item

label

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

@en

prefLabel

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

@en

P1476

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

@en

P2093

Benjamin Yaw Owusu

http://www.w3.org/2001/XMLSchema#string

Lidija Klampfer

http://www.w3.org/2001/XMLSchema#string

Robert Galemmo

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Hallmarks of Cancer: The Next Generation

Molecular cloning and expression of human hepatocyte growth factor

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer

Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Matrix crosslinking forces tumor progression by enhancing integrin signaling

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

P31

scholarly article

P356

10.3390/CANCERS9040035

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James W. Janetka

P577

2017-04-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28420162

http://www.w3.org/2001/XMLSchema#string

P932

5406710

http://www.w3.org/2001/XMLSchema#string

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

about

P2860

P2860

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932